Evidence map›Paper›PMID 37920452›Full record

ArticleAdvanced functional materials2022

Molecularly Tailored Interface for Long-Term Xenogeneic Cell Transplantation.

Sajeesh Kumar Madhurakkat Perikamana, Nailah Seale, Jiaul Hoque, Ji Hyun Ryu, Vardhman Kumar, Yuru Vernon Shih, Shyni Varghese

Open access · greenAbstract read
In one paragraph

Article in Advanced functional materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sajeesh Kumar Madhurakkat PerikamanaDepartment of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Nailah SealeDepartment of Bioengineering University of California-San Diego La Jolla, CA 92093, USA.
Jiaul HoqueDepartment of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Ji Hyun RyuDepartment of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Vardhman KumarDepartment of Biomedical Engineering Duke University Durham, NC 27710, USA.
Yuru Vernon ShihDepartment of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Shyni VargheseDepartment of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Duke University · USUniversity of California San Diego · US

Funding

Adenosine A2B Receptor in Bone Health and OsteoporosisR01AR071552 · NIAMS · DUKE UNIVERSITY · PI VARGHESE, SHYNI · 2017 to 2021
$2.4M
Diversity Supplement -"Bioinspired Synthetic Grafts for Bone Regeneration"R01AR063184 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARGHESE, SHYNI · 2013 to 2017
$1.7M
NIAMS NIH HHS R01 AR063184NIAMS NIH HHS R01 AR071552
6 · The paper itself

Abstract

Encapsulation of therapeutic cells in a semipermeable device can mitigate the need for systemic immune suppression following cell transplantation by providing local immunoprotection while being permeable to nutrients, oxygen, and different cell-secreted biomolecules. However, fibrotic tissue deposition around the device has been shown to compromise the long-term function of the transplanted cells. Herein, a macroencapsulation device design that improves long-term survival and function of the transplanted cells is reported. The device is comprised of a semipermeable chitosan pouch with a tunable reservoir and molecularly engineered interface. The chitosan pouch interface decorated with 1,12-dodecanedioic acid (DDA), limits the cell adhesion and vigorous foreign body response while maintaining the barrier properties amenable to cell encapsulation. The device provides long-term protection to the encapsulated human primary hepatocytes in the subcutaneous space of immunocompetent mice. The device supports the encapsulated cells for up to 6 months as evident from cell viability and presence of human specific albumin in circulation. Solutions that integrate biomaterials and interfacial engineering such as the one described here may advance development of easy-to manufacture and retrievable devices for the transplantation of therapeutic cells in the absence of immunosuppression.

Indexed as

cell encapsulation deviceforeign body responseimmune isolationxenogeneic cell transplantation

Identifiers

PMID37920452
PMCPMC10622113
OpenAlexW3206537678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.